| HOME >> MEDICINE >> TECHNOLOGY |
$
7,279,757$
8,623,265Diluted EPS - Non GAAP$
0.27$
0.33Non-cash employee stock compensation$
(1,470,795)$
(1,247,977)Loss from change in fair value of warrants
$
-$
(3,086,285)Impairment loss of goodwill
$
-$
-Loss on abandonment of long-lived assets attributable to controlling interest
$
-$
-Written-off of raw material attributable to controlling interest due to closure of plasma stations
$
-$
345,704Net Income Attributable to the Company
$
5,808,962$
4,634,707Weighted average number of shares used in computation of Non GAAP diluted EPS27,147,35126,425,216For the year endedFor the year ended12/31/201212/31/2011Net IncomeNet IncomeAdjusted Net Income Attributable to the Company - Non GAAP
$
47,997,976$
36,502,178Diluted EPS - Non GAAP$
1.79$
1.37Non-cash employee stock compensation$
(4,544,927)$
(4,896,232)Impairment loss of goodwill
$
-$
(18,160,281)Loss on abandonment of long-lived assets attributable to controlling interest
$
-$
(3,565,635)Written-off of raw material attributable to controlling interest due to closure of plasma stations
$
-$
(90,506)Interest on the Notes$
-$
(3,582,648)Gain from change in fair value of embedded conversion option in the Notes
$
-$
6,289,661Gain from change in fair value of warrants
$
1,769,140$
5,685,173Net Income Attributable to the Company
$
45,222,189$
18,181,710Weighted average number of shares used in computation of Non GAAP diluted EPS26,839,72326,654,662
| SOURCE China Biologic Products, Inc. Copyright©2012 PR Newswire. All rights reserved |